antipyrine has been researched along with Chronic Illness in 47 studies
Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)
antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hepatic drug metabolism was examined in patients with chronic pancreatitis and healthy controls by using a cocktail design with three different model compounds: antipyrine to express phase-I oxidation, oxazepam to express phase-II conjugation, and indocyanine green (ICG), a high-clearance compound." | 9.09 | Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ( Andersen, V; Larsen, S; Sonne, J, 1999) |
| "The present study was performed to establish whether sequential determinations of antipyrine clearance, using a simplified two-point test, are sensitive and specific indicators of changes in chronic hepatitis B disease activity." | 9.06 | Serial antipyrine clearance studies detect altered hepatic metabolic function during spontaneous and interferon-induced changes in chronic hepatitis B disease activity. ( Farrell, GC; Williams, SJ, 1989) |
| "The authors examined the activity of N-acetyltransferase and that of microsomal P-450 isoenzymes in health and hepatic disease state by determining the acetylation phenotype and the total (CLAP) and metabolic clearances of antipyrine to form norantipyrine or N-demethylantipyrine (MCLnora), 3-hydroxymethylantipyrine (MCLhma), and 4-hydroxyantipyrine (MCLha) in 21 healthy subjects and in 33 patients with chronic liver diseases (CLD) and investigated the relationship between the activities of these two enzyme systems." | 7.69 | Relationship between antipyrine metabolism and acetylation phenotype in health and chronic liver diseases. ( Ali, H; Dossing, M; el-Yazigi, A; Ernst, P; Raines, DA; Sieck, JO; Wahab, FA, 1995) |
| "Our aim was to study whether chronic hepatitis C affects the three metabolic pathways of the model drug antipyrine differently." | 7.69 | Antipyrine clearance and metabolite excretion in patients with chronic hepatitis C. ( Ali, HA; Ali, MA; Døssing, M; el-Yazigi, A; Ernst, P; Khan, B; Raines, DA; Saour, J; Sieck, JO, 1995) |
| "Blood clearance of antipyrine, indocyanine green, and galactose were measured to evaluate the alterations of effective hepatic blood flow and hepatic intrinsic clearances in chronic liver diseases." | 7.67 | Hepatic clearances of antipyrine, indocyanine green, and galactose in normal subjects and in patients with chronic liver diseases. ( Beppu, T; Hanano, M; Idezuki, Y; Iga, T; Kawasaki, S; Sanjo, K; Sugiura, M; Sugiyama, Y, 1988) |
| "NA-3,4-DCM, dosed systemically (intraperitoneally or per os), was capable of interfering with the development of mechanical hypernociception induced by intraplantar injection of carrageenan and complete Freund adjuvant in mice." | 5.36 | N-antipyrine-3, 4-dichloromaleimide, an effective cyclic imide for the treatment of chronic pain: the role of the glutamatergic system. ( Antonialli, CS; Corrêa, R; da Silva, GF; de Campos-Buzzi, F; Filho, VC; Quintão, NL, 2010) |
| "Hepatic drug metabolism was examined in patients with chronic pancreatitis and healthy controls by using a cocktail design with three different model compounds: antipyrine to express phase-I oxidation, oxazepam to express phase-II conjugation, and indocyanine green (ICG), a high-clearance compound." | 5.09 | Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ( Andersen, V; Larsen, S; Sonne, J, 1999) |
| "The present study was performed to establish whether sequential determinations of antipyrine clearance, using a simplified two-point test, are sensitive and specific indicators of changes in chronic hepatitis B disease activity." | 5.06 | Serial antipyrine clearance studies detect altered hepatic metabolic function during spontaneous and interferon-induced changes in chronic hepatitis B disease activity. ( Farrell, GC; Williams, SJ, 1989) |
| "The authors examined the activity of N-acetyltransferase and that of microsomal P-450 isoenzymes in health and hepatic disease state by determining the acetylation phenotype and the total (CLAP) and metabolic clearances of antipyrine to form norantipyrine or N-demethylantipyrine (MCLnora), 3-hydroxymethylantipyrine (MCLhma), and 4-hydroxyantipyrine (MCLha) in 21 healthy subjects and in 33 patients with chronic liver diseases (CLD) and investigated the relationship between the activities of these two enzyme systems." | 3.69 | Relationship between antipyrine metabolism and acetylation phenotype in health and chronic liver diseases. ( Ali, H; Dossing, M; el-Yazigi, A; Ernst, P; Raines, DA; Sieck, JO; Wahab, FA, 1995) |
| "Our aim was to study whether chronic hepatitis C affects the three metabolic pathways of the model drug antipyrine differently." | 3.69 | Antipyrine clearance and metabolite excretion in patients with chronic hepatitis C. ( Ali, HA; Ali, MA; Døssing, M; el-Yazigi, A; Ernst, P; Khan, B; Raines, DA; Saour, J; Sieck, JO, 1995) |
| "Studies of the immune status and antipyrine test helped to analyse the status of the two body detoxicants--the immune system and the system of microsomal hepatic oxygenases in petrochemical production workers suffering from the chronic bronchitis and bronchial asthma." | 3.68 | [The function of 2 detoxifying body systems in workers of the petrochemical industry]. ( Ershov, AF; Mazurov, AL; Potapova, GV; Saprykina, EV, 1992) |
| "Correlations between the clinical course of true eczema and liver monooxigenase system, assessed by antipyrine test, were investigated in patients suffering from the condition." | 3.68 | [The mono-oxygenase enzyme system of the liver in patients with true eczema]. ( Akovbian, VA; Ashirmetov, AKh; Krakovskiĭ, ME; Tikhonova, NN, 1990) |
| "Blood clearance of antipyrine, indocyanine green, and galactose were measured to evaluate the alterations of effective hepatic blood flow and hepatic intrinsic clearances in chronic liver diseases." | 3.67 | Hepatic clearances of antipyrine, indocyanine green, and galactose in normal subjects and in patients with chronic liver diseases. ( Beppu, T; Hanano, M; Idezuki, Y; Iga, T; Kawasaki, S; Sanjo, K; Sugiura, M; Sugiyama, Y, 1988) |
| " Multiple relationships were revealed, but generally valid correlations for the group of liver diseases occurred only in special relationships (serum albumin level and antipyrine T1/2; serum bilirubin level and sulphadimidine T1/2)." | 3.66 | Correlation between biochemical tests, parameters of drug elimination and hepatic enzyme induction in chronic liver diseases. ( Beró, T; Fábián, C; Horváth, T; Jávor, T; Kádas, I; Pár, A, 1983) |
| "The plasma half lives of antipyrine, paracetamol, and lignocaine given by mouth were measured in 23 patients with stable chronic liver diseases of varying severity." | 3.65 | Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease. ( Adjepon-Yamoah, KK; Finlayson, ND; Forrest, JA; Prescott, LF, 1977) |
| " A Bayesian approach was developed to determine the individual pharmacokinetic parameters of phenazone." | 2.67 | Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters. ( Bouvet, O; Bressolle, F; Dubois, A; Fabre, D; Galtier, M; Goméni, R; Gris, JC; Raffanel, C, 1993) |
| "NA-3,4-DCM, dosed systemically (intraperitoneally or per os), was capable of interfering with the development of mechanical hypernociception induced by intraplantar injection of carrageenan and complete Freund adjuvant in mice." | 1.36 | N-antipyrine-3, 4-dichloromaleimide, an effective cyclic imide for the treatment of chronic pain: the role of the glutamatergic system. ( Antonialli, CS; Corrêa, R; da Silva, GF; de Campos-Buzzi, F; Filho, VC; Quintão, NL, 2010) |
| "Edaravone was administrated intraperitoneally per day at a dose of 4 mg/kg." | 1.35 | Edaravone, a free radical scavenger, is effective on neuropathic pain in rats. ( Deng, XM; Mao, YF; Sun, JH; Xiong, YC; Xu, H; Yan, N, 2009) |
| " We conclude that, although propranolol may have some influence on drug handling acutely, chronic administration does not interfere with hepatic drug metabolism or renal drug clearance." | 1.28 | Effect of acute and chronic propranolol administration on antipyrine and paracetamol clearance in patients with chronic liver disease. ( Bouchier, IA; Hayes, PC, 1989) |
| "Antipyrine half-life was measured in the 12 patients while they continued to receive the drug." | 1.26 | Induction of microsomal enzyme activity by flupenthixol in chronic schizophrenics. ( King, DJ; McDevitt, DG; Salem, SA, 1982) |
| "Antipyrine (10 mg/kg) was given orally and assayed in saliva by gas-liquid chromatography." | 1.26 | Salivary antipyrine kinetics in hepatic and renal disease and in patients on anticonvulsant therapy. ( Clarkson, AR; Frewin, DB; Harman, AW; Penhall, RK; Phillips, PJ; Priestly, BG, 1977) |
| "Antipyrine disposition was also measured in each subject." | 1.26 | Antipyrine clearance per unit volume liver: an assessment of hepatic function in chronic liver disease. ( Branch, RA; Halliwell, M; Homeida, M; Read, AE; Roberts, CJ, 1979) |
| "Antipyrine metabolism was normal or marginally impaired in patients with compensated cirrhosis or acute hepatitis, whereas it was frequently abnormal in those with chronic active hepatitis or advanced alcoholic liver disease." | 1.26 | Drug metabolism in liver disease. Identification of patients with impaired hepatic drug metabolism. ( Cooksley, WG; Farrell, GC; Hart, P; Powell, LW, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 33 (70.21) | 18.7374 |
| 1990's | 10 (21.28) | 18.2507 |
| 2000's | 2 (4.26) | 29.6817 |
| 2010's | 2 (4.26) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jangra, A | 1 |
| Sriram, CS | 1 |
| Dwivedi, S | 1 |
| Gurjar, SS | 1 |
| Hussain, MI | 1 |
| Borah, P | 1 |
| Lahkar, M | 1 |
| Mao, YF | 1 |
| Yan, N | 1 |
| Xu, H | 1 |
| Sun, JH | 1 |
| Xiong, YC | 1 |
| Deng, XM | 1 |
| Ueno, Y | 1 |
| Zhang, N | 1 |
| Miyamoto, N | 1 |
| Tanaka, R | 1 |
| Hattori, N | 1 |
| Urabe, T | 1 |
| Quintão, NL | 1 |
| da Silva, GF | 1 |
| Antonialli, CS | 1 |
| de Campos-Buzzi, F | 1 |
| Corrêa, R | 1 |
| Filho, VC | 1 |
| Bircher, J | 1 |
| Horváth, T | 1 |
| Pár, A | 1 |
| Beró, T | 1 |
| Kádas, I | 1 |
| Fábián, C | 1 |
| Jávor, T | 1 |
| Salem, SA | 1 |
| King, DJ | 1 |
| McDevitt, DG | 1 |
| Okolicsànyi, L | 1 |
| Orlando, R | 1 |
| Lirussi, F | 1 |
| Naccarato, R | 1 |
| Dal Brun, G | 1 |
| Geller, LI | 1 |
| Griaznova, MV | 1 |
| Bulgakova, OS | 1 |
| Kozlova, ZP | 1 |
| Kuntz, HD | 1 |
| Meessen, D | 1 |
| May, B | 1 |
| Habior, A | 1 |
| el-Yazigi, A | 2 |
| Raines, DA | 2 |
| Wahab, FA | 1 |
| Sieck, JO | 2 |
| Ernst, P | 2 |
| Ali, H | 1 |
| Dossing, M | 1 |
| Ali, HA | 1 |
| Ali, MA | 1 |
| Saour, J | 1 |
| Khan, B | 1 |
| Døssing, M | 1 |
| Loginov, AS | 1 |
| Bendikov, EA | 1 |
| Petrakov, AV | 1 |
| Fabre, D | 1 |
| Bressolle, F | 1 |
| Goméni, R | 1 |
| Bouvet, O | 1 |
| Dubois, A | 1 |
| Raffanel, C | 1 |
| Gris, JC | 1 |
| Galtier, M | 1 |
| Jahnson, S | 1 |
| Holtz, A | 1 |
| Gerdin, B | 1 |
| Andersen, V | 1 |
| Sonne, J | 1 |
| Larsen, S | 1 |
| Harman, AW | 1 |
| Penhall, RK | 1 |
| Priestly, BG | 1 |
| Frewin, DB | 1 |
| Phillips, PJ | 1 |
| Clarkson, AR | 1 |
| Bengtsson, U | 1 |
| Homeida, M | 1 |
| Roberts, CJ | 1 |
| Halliwell, M | 1 |
| Read, AE | 4 |
| Branch, RA | 4 |
| Agnihotri, SN | 1 |
| Clark, RA | 1 |
| Cooper, S | 1 |
| Iyun, AO | 1 |
| Tucker, GT | 1 |
| Farrell, GC | 2 |
| Cooksley, WG | 1 |
| Hart, P | 1 |
| Powell, LW | 1 |
| McLean, A | 1 |
| du Souich, P | 1 |
| Gibaldi, M | 1 |
| Prescott, LF | 4 |
| Forrest, JA | 3 |
| Adjepon-Yamoah, KK | 4 |
| Finlayson, ND | 3 |
| James, JA | 3 |
| Mazurov, AL | 1 |
| Potapova, GV | 1 |
| Saprykina, EV | 1 |
| Ershov, AF | 1 |
| Ashirmetov, AKh | 1 |
| Akovbian, VA | 1 |
| Krakovskiĭ, ME | 1 |
| Tikhonova, NN | 1 |
| Barry, M | 1 |
| Keeling, PW | 1 |
| Feely, J | 1 |
| Kagaya, Y | 1 |
| Kanno, Y | 1 |
| Takeyama, D | 1 |
| Ishide, N | 1 |
| Maruyama, Y | 1 |
| Takahashi, T | 1 |
| Ido, T | 1 |
| Takishima, T | 1 |
| Gorchakova, LA | 1 |
| Dynnik, OB | 1 |
| Poddubnyĭ, NM | 1 |
| Romanenko, VA | 1 |
| Taranenko, NB | 1 |
| Prokhorenko, OA | 1 |
| Hayes, PC | 1 |
| Bouchier, IA | 1 |
| Williams, SJ | 1 |
| Chichenina, IV | 2 |
| Khakimov, ZZ | 1 |
| Rakhmatov, AB | 1 |
| Zalialieva, MV | 1 |
| Kawasaki, S | 1 |
| Sugiyama, Y | 1 |
| Iga, T | 1 |
| Hanano, M | 1 |
| Beppu, T | 1 |
| Sugiura, M | 1 |
| Sanjo, K | 1 |
| Idezuki, Y | 1 |
| Kupcová, V | 1 |
| Holomán, J | 1 |
| Turecký, L | 1 |
| Ulicná, O | 1 |
| Brixová, E | 1 |
| Gerlach, E | 1 |
| Nimmo, J | 1 |
| Nanra, RS | 1 |
| Kincaid-Smith, P | 1 |
| Ackermann, E | 1 |
| Renger, F | 1 |
| Dökert, B | 1 |
| Walther, M | 1 |
| Gundert-Remy, U | 1 |
| Marquardt, R | 1 |
| Andritsch, F | 1 |
| Weber, E | 1 |
| Mährlein, W | 1 |
| Krause, M | 1 |
| Drtil, J | 1 |
| Sandz, Z | 1 |
4 reviews available for antipyrine and Chronic Illness
| Article | Year |
|---|---|
Quantitative assessment of deranged hepatic function: a missed opportunity?
Topics: Adult; Aminopyrine; Antipyrine; Blood Circulation; Breath Tests; Chronic Disease; Galactose; Humans; | 1983 |
Prevention of renal disease.
Topics: Anti-Glomerular Basement Membrane Disease; Antipyrine; Caffeine; Chronic Disease; Female; Glomerulon | 1979 |
Drug metabolism in liver disease.
Topics: Acetaminophen; Acute Disease; Antipyrine; Chemical and Drug Induced Liver Injury; Chronic Disease; H | 1975 |
Chronic effect of analgesics on the kidney.
Topics: Aminopyrine; Analgesics; Animals; Antipyrine; Aspirin; Caffeine; Chronic Disease; Drug Combinations; | 1972 |
5 trials available for antipyrine and Chronic Illness
| Article | Year |
|---|---|
[Pharmaco-metabolic activity in chronic hepatopathies: influence of treatment with UDPG].
Topics: Adult; Aged; Antipyrine; Chronic Disease; Clinical Trials as Topic; Female; Hepatitis; Humans; Liver | 1980 |
Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters.
Topics: Adult; Aged; Antipyrine; Bayes Theorem; Body Fluid Compartments; Chronic Disease; Female; Humans; Li | 1993 |
Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Chronic Disease; Coloring Agents; Female | 1999 |
Major determinants of drug disposition in chronic liver disease: a study with indocyanine green and antipyrine [proceedings].
Topics: Antipyrine; Chronic Disease; Humans; Indocyanine Green; Liver; Liver Diseases | 1975 |
Serial antipyrine clearance studies detect altered hepatic metabolic function during spontaneous and interferon-induced changes in chronic hepatitis B disease activity.
Topics: Adult; Alanine Transaminase; Antipyrine; Chronic Disease; Female; Hepatitis B; Hepatitis B e Antigen | 1989 |
38 other studies available for antipyrine and Chronic Illness
| Article | Year |
|---|---|
Sodium Phenylbutyrate and Edaravone Abrogate Chronic Restraint Stress-Induced Behavioral Deficits: Implication of Oxido-Nitrosative, Endoplasmic Reticulum Stress Cascade, and Neuroinflammation.
Topics: Animals; Antipyrine; Chronic Disease; Depression; Dose-Response Relationship, Drug; Edaravone; Endop | 2017 |
Edaravone, a free radical scavenger, is effective on neuropathic pain in rats.
Topics: Analgesics; Animals; Antipyrine; Blotting, Western; Cells, Cultured; Chronic Disease; Edaravone; Fre | 2009 |
Edaravone attenuates white matter lesions through endothelial protection in a rat chronic hypoperfusion model.
Topics: Animals; Antipyrine; Apoptosis; Axons; Blood-Brain Barrier; Brain; Brain Ischemia; Cell Proliferatio | 2009 |
N-antipyrine-3, 4-dichloromaleimide, an effective cyclic imide for the treatment of chronic pain: the role of the glutamatergic system.
Topics: Administration, Oral; Analgesics; Animals; Antipyrine; Behavior, Animal; Carrageenan; Chronic Diseas | 2010 |
Correlation between biochemical tests, parameters of drug elimination and hepatic enzyme induction in chronic liver diseases.
Topics: Adult; Antipyrine; Bilirubin; Chronic Disease; Enzyme Induction; Female; Glucaric Acid; Humans; Kine | 1983 |
Induction of microsomal enzyme activity by flupenthixol in chronic schizophrenics.
Topics: Adult; Aged; Antipyrine; Chronic Disease; Enzyme Induction; Flupenthixol; Half-Life; Humans; Microso | 1982 |
[Pharmacometabolic capacity of the liver and the effect of pancreozymin in chronic hepatitis, chronic pancreatitis and diabetes mellitus].
Topics: Adult; Antipyrine; Biotransformation; Cholecystokinin; Chronic Disease; Diabetes Mellitus; Hepatitis | 1982 |
[Hepatic elimination of indocyanine green and antipyrine in patients with chronic liver disease].
Topics: Antipyrine; Chronic Disease; Hepatitis; Humans; Indocyanine Green; Liver Diseases; Liver Function Te | 1982 |
[Endogenous bile acids in the blood as a functional test in chronic liver diseases. I. Comparison with the antipyrine elimination test].
Topics: Adult; Aged; Antipyrine; Bile Acids and Salts; Chronic Disease; Female; Hepatitis B; Hepatitis, Chro | 1982 |
Relationship between antipyrine metabolism and acetylation phenotype in health and chronic liver diseases.
Topics: Acetylation; Adult; Antipyrine; Arylamine N-Acetyltransferase; Chronic Disease; Cytochrome P-450 Enz | 1995 |
Antipyrine clearance and metabolite excretion in patients with chronic hepatitis C.
Topics: Adult; Antipyrine; Chronic Disease; Edaravone; Female; Hepatitis C; Humans; Male; Middle Aged; Refer | 1995 |
[Lipid peroxidation markers in the exhaled breath and microsomal oxidation in patients with chronic diffuse liver diseases].
Topics: Adult; Antipyrine; Biomarkers; Breath Tests; Butanes; Chronic Disease; Female; Humans; Lipid Peroxid | 1995 |
Anastomotic blood-flow reduction in rat small intestine with chronic radiation damage.
Topics: Anastomosis, Surgical; Animals; Antipyrine; Autoradiography; Blood Flow Velocity; Body Weight; Carbo | 1998 |
Salivary antipyrine kinetics in hepatic and renal disease and in patients on anticonvulsant therapy.
Topics: Adult; Aged; Anticonvulsants; Antipyrine; Chronic Disease; Female; Half-Life; Humans; Kidney Failure | 1977 |
Antipyrine clearance per unit volume liver: an assessment of hepatic function in chronic liver disease.
Topics: Aged; Antipyrine; Body Weight; Chronic Disease; Humans; Liver; Liver Diseases; Liver Function Tests; | 1979 |
Chronic pulmonary disease and antipyrine disposition.
Topics: Adult; Aged; Antipyrine; Chronic Disease; Female; Humans; Lung Diseases; Male; Middle Aged; Oxygen I | 1978 |
Drug metabolism in liver disease. Identification of patients with impaired hepatic drug metabolism.
Topics: Acute Disease; Antipyrine; Ascites; Biotransformation; Chemical and Drug Induced Liver Injury; Chole | 1978 |
Noninvasive kinetic approach to the estimation of total hepatic blood flow and shunting in chronic liver disease--a hypothesis.
Topics: Antipyrine; Chronic Disease; Humans; Indocyanine Green; Kinetics; Liver; Liver Circulation; Liver Di | 1979 |
Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease.
Topics: Acetaminophen; Adult; Aged; Antipyrine; Chronic Disease; Female; Half-Life; Humans; Kinetics; Lidoca | 1977 |
Proceedings: Antipyrine, lingocaine and paracetamol metabolism in chronic liver disease.
Topics: Acetaminophen; Adult; Aged; Antipyrine; Chronic Disease; Female; Humans; Lidocaine; Liver Diseases; | 1975 |
The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic lever disease.
Topics: Adult; Aged; Antipyrine; Bilirubin; Chronic Disease; Female; Half-Life; Humans; Indocyanine Green; K | 1976 |
[The function of 2 detoxifying body systems in workers of the petrochemical industry].
Topics: Adult; Antipyrine; Asthma; Bronchitis; Chemical Industry; Chronic Disease; Cytochrome P-450 Enzyme S | 1992 |
[The mono-oxygenase enzyme system of the liver in patients with true eczema].
Topics: Adolescent; Adult; Antipyrine; Chronic Disease; Dermatitis, Exfoliative; Eczema; Female; Half-Life; | 1990 |
Tissue zinc status and drug elimination in patients with chronic liver disease.
Topics: Antipyrine; Chronic Disease; Female; Humans; Leukocytes; Liver Cirrhosis; Male; Metabolic Clearance | 1990 |
Effects of long-term pressure overload on regional myocardial glucose and free fatty acid uptake in rats. A quantitative autoradiographic study.
Topics: Acute Disease; Animals; Antipyrine; Autoradiography; Blood Glucose; Chronic Disease; Fatty Acids; Fa | 1990 |
[Antipyrine test in the diagnosis of chronic cholecystitis].
Topics: Adolescent; Adult; Antipyrine; Biotransformation; Cholecystitis; Chronic Disease; Humans; Microsomes | 1989 |
Effect of acute and chronic propranolol administration on antipyrine and paracetamol clearance in patients with chronic liver disease.
Topics: Acetaminophen; Adult; Aged; Antipyrine; Chronic Disease; Drug Administration Schedule; Female; Human | 1989 |
[The function of the monooxygenase system of the liver in patients with psoriasis].
Topics: Adolescent; Adult; Antipyrine; Benzhydryl Compounds; Chronic Disease; Drug Therapy, Combination; Enz | 1989 |
[Interrelation of monooxygenase activity and the function of the immune system in psoriasis patients].
Topics: Adult; Antipyrine; Chronic Disease; Female; Humans; Immune System; Immunity, Cellular; Liver; Male; | 1988 |
Hepatic clearances of antipyrine, indocyanine green, and galactose in normal subjects and in patients with chronic liver diseases.
Topics: Adult; Aged; Antipyrine; Chronic Disease; Female; Galactose; Galactosemias; Hepatitis; Humans; Indoc | 1988 |
[Changes in metabolic function of the liver in patients with chronic hepatic diseases].
Topics: Antipyrine; Chronic Disease; Half-Life; Hepatitis; Humans; Liver; Liver Cirrhosis | 1985 |
[Significance of ichthyol in gynecology].
Topics: Acute Disease; Adolescent; Adult; Anti-Bacterial Agents; Antipyrine; Atropa belladonna; Barbiturates | 1969 |
Gross impairment of hepatic drug metabolism in a patient with chronic liver disease.
Topics: Adult; Antipyrine; Biotransformation; Chronic Disease; Female; Half-Life; Hepatitis; Humans; Jaundic | 1974 |
Proceedings: The influence of chronic liver disease on the elimination of d-propranolol, anti-pyrine, and indocyanine green.
Topics: Administration, Oral; Antipyrine; Bilirubin; Chronic Disease; Humans; Indocyanine Green; Liver; Live | 1974 |
[Aminophenazone half life in patients with chronic liver parenchyma disorders].
Topics: Aminopyrine; Animals; Antipyrine; Chronic Disease; Fatty Liver; Female; Half-Life; Hepatitis; Humans | 1972 |
[Induction of drug-catabolizing enzymes in chronic alcoholics].
Topics: Alcoholism; Antipyrine; Chronic Disease; Enzyme Induction; Humans; Microsomes, Liver; Pharmaceutical | 1974 |
[Modification of ventilation disturbances in chronic obstructive pulmonary emphysema by Pulmophylline].
Topics: Antipyrine; Chronic Disease; Humans; Male; Pulmonary Emphysema; Respiration; Theophylline | 1969 |
[Changes in the gastric mucosa following the use of various antiasthmatics and analgesics-antipyretics].
Topics: Adult; Analgesics; Antipyrine; Barbiturates; Bronchodilator Agents; Caffeine; Chronic Disease; Gastr | 1968 |